Literature DB >> 11206684

Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group.

R A Kloner1, M Brown, L M Prisant, M Collins.   

Abstract

Oral sildenafil is an effective treatment for erectile dysfunction (ED), which is a common complaint for patients with hypertension and those taking antihypertensive agents. This post hoc subanalysis assessed the efficacy and safety of sildenafil in men with ED who were receiving concomitant antihypertensive medication. Efficacy was assessed in 3414 men (1218 of whom were taking antihypertensive medication) who received sildenafil (5 to 200 mg) or placebo for 6 weeks to 6 months in 10 double-blind, placebo-controlled studies. The significant improvements in erectile function demonstrated by sildenafil-treated patients were comparable in patients taking and those not taking antihypertensive medication. Safety was assessed in 3975 men (1094 of whom were taking one or more antihypertensive agent, classified as a diuretic, beta-blocker, alpha1-blocker, angiotensin converting enzyme inhibitor, or calcium channel blocker), who received sildenafil or placebo in 18 double-blind, placebo-controlled studies. For patients taking sildenafil and antihypertensive medication, the incidence of treatment-related adverse events (34%) was similar to that for sildenafil-treated patients not taking any antihypertensive agent (38%). The incidences of the most common adverse events and of adverse events potentially related to blood pressure decreases (eg, hypotension, dizziness, and syncope) were similar in both sildenafil groups. The number of antihypertensive medications taken from among the five classes had no effect on the adverse event profile of sildenafil. Sildenafil is an effective and well-tolerated treatment for ED in patients taking concomitant antihypertensive medication, including those on multidrug regimens.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11206684     DOI: 10.1016/s0895-7061(00)01177-8

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  31 in total

Review 1.  Clinical update on sildenafil citrate.

Authors:  Ian H Osterloh; Alan Riley
Journal:  Br J Clin Pharmacol       Date:  2002-03       Impact factor: 4.335

Review 2.  Erectile dysfunction and atherosclerosis.

Authors:  Robert A Kloner; Mark Speakman
Journal:  Curr Atheroscler Rep       Date:  2002-09       Impact factor: 5.113

Review 3.  [Erectile dysfunction. New drugs with special consideration of the PDE 5 inhibitors].

Authors:  H Porst
Journal:  Urologe A       Date:  2004-07       Impact factor: 0.639

Review 4.  Sexual activity and ischemic heart disease.

Authors:  Richard A Lange; Glenn N Levine
Journal:  Curr Cardiol Rep       Date:  2014-02       Impact factor: 2.931

5.  An Evaluation of a Clinical Care Pathway for the Management of Men With Nonorganic Erectile Dysfunction.

Authors:  Lawrence C Jenkins; Matthew Hall; Serkan Deveci; Patricia Guhring; Marilyn Parker; Christian J Nelson; John P Mulhall
Journal:  J Sex Med       Date:  2019-08-20       Impact factor: 3.802

Review 6.  Phosphodiesterase-5 inhibitors and their hemodynamic effects.

Authors:  L Michael Prisant
Journal:  Curr Hypertens Rep       Date:  2006-08       Impact factor: 5.369

Review 7.  Evaluation and Management of Erectile Dysfunction in the Hypertensive Patient.

Authors:  Jay Pravin Patel; Eric Hweegeun Lee; Carlos Ignacio Mena-Hurtado; Charles N Walker
Journal:  Curr Cardiol Rep       Date:  2017-08-24       Impact factor: 2.931

Review 8.  Cardiovascular safety of sildenafil.

Authors:  Diane Tran; Laurence Guy Howes
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 9.  Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions.

Authors:  Ajay Nehra
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

Review 10.  Assessment of cardiovascular risk in patients with erectile dysfunction: focus on the diabetic patient.

Authors:  Robert A Kloner
Journal:  Endocrine       Date:  2004 Mar-Apr       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.